Cytogen to license prostate test technology:
This article was originally published in Clinica
Executive Summary
Cytogen plans to obtain an exclusive, worldwide licence to Molecular Staging's Rolling Circle Amplification Technology (RCAT) to develop in vitro tests for prostate specific membrane antigen (PSMA) and prostate specific antigen (PSA). According to Princeton, New Jersey-based Cytogen, serum PSMA is increased in prostate cancer, but appears to be unaffected by other miscellaneous events, unlike PSA. Cytogen plans to use the RCAT technology to develop a PSMA and PSA test for prostate cancer and hopes to have an assay for clinical study by mid-2000.